Andrei Seluanov

The evidence shows a credible mechanistic research direction—linking cGAS loss, chromatin disruption, transposable-element activation, inflammation, and accelerated aging—and an example of translating comparative-biology findings toward therapy. However, it does not establish that Seluanov has publicly articulated a concrete, durable vision for ending aging, reversing biological decline, or materially extending healthy human lifespan.

Seluanov demonstrates field-defining scientific influence in genome stability, transposable elements, DNA repair, inflammation, and comparative cancer resistance. His h-index of 73 and nearly 20,000 citations are reinforced by numerous heavily cited papers, including several directly central to aging biology. The evidence supports exceptional academic impact, though not the very highest score because authorship-specific contributions and broader field-wide leadership are not independently detailed.

The evidence establishes substantial scientific activity but identifies zero investments, donations, catalytic positions, or capital-backed longevity outcomes. Scientific publications and citations do not constitute capital deployment, so this dimension is inapplicable rather than merely low-scoring.

No public investment, donation, or other capital-deployment activity is evidenced for this scientist.

Seluanov shows a coherent scientific bet on learning from unusually long-lived mammals, connecting comparative biology to genome stability, cancer resistance, and potential translation. The naked-mole-rat hyaluronan program is a particularly distinctive choice that produced an influential mechanistic finding and later a therapeutic path. However, the supplied evidence does not establish when or why he formed this thesis, how contrarian it was at inception, or whether his choices were counterfactually decisive for the field.

Field creation is applicable, but the evidence shows Seluanov participating in established aging-research structures rather than creating a new organization, program, category, community, protocol, or funding path. His executive-committee role and participation in a major collaborative project indicate some field-supporting activity, but not demonstrated field-building leadership.

The dimension is applicable, but the supplied evidence documents scientific productivity rather than public risk-taking or conviction. No qualifying bravery exhibit, career sacrifice, sustained stand under criticism, personally significant bet, or self-experimentation is shown.

Seluanov demonstrates meaningful second-order leverage primarily through broad scholarly influence and extensive cross-institutional collaboration. His highly cited research has helped propagate work on genome stability, cancer resistance, and comparative longevity, while large multi-author projects show an ability to convene or participate in substantial research networks. However, the evidence does not establish organization-building, capital mobilization, policy influence, public legitimacy, or attributable follow-on ventures, limiting the score.